Does PIMECROLIMUS Cause Product use in unapproved indication? 86 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 86 reports of Product use in unapproved indication have been filed in association with PIMECROLIMUS (Pimecrolimus). This represents 6.5% of all adverse event reports for PIMECROLIMUS.
86
Reports of Product use in unapproved indication with PIMECROLIMUS
6.5%
of all PIMECROLIMUS reports
1
Deaths
1
Hospitalizations
How Dangerous Is Product use in unapproved indication From PIMECROLIMUS?
Of the 86 reports, 1 (1.2%) resulted in death, 1 (1.2%) required hospitalization.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PIMECROLIMUS. However, 86 reports have been filed with the FAERS database.
What Other Side Effects Does PIMECROLIMUS Cause?
Drug ineffective (349)
Treatment failure (139)
Psoriasis (114)
Off label use (113)
Pruritus (94)
Erythema (89)
Rash (82)
Application site pain (72)
Therapeutic product effect incomplete (65)
Condition aggravated (59)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
Which PIMECROLIMUS Alternatives Have Lower Product use in unapproved indication Risk?
PIMECROLIMUS vs PIMOZIDE
PIMECROLIMUS vs PINAVERIUM
PIMECROLIMUS vs PINDOLOL
PIMECROLIMUS vs PIOGLITAZONE
PIMECROLIMUS vs PIPAMPERONE